Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 5
2003 6
2004 7
2005 13
2006 17
2007 19
2008 12
2009 15
2010 39
2011 36
2012 59
2013 63
2014 75
2015 66
2016 62
2017 82
2018 102
2019 112
2020 145
2021 152
2022 183
2023 190
2024 210
2025 277
2026 97

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,815 results

Results by year

Filters applied: . Clear all
Page 1
Targeting FOXM1 condensates reduces breast tumour growth and metastasis.
Xie F, Zhou X, Ran Y, Li R, Zou J, Wan S, Su P, Meng X, Yan H, Lu H, Ru H, Hu H, Mao Z, Yang B, Zhou F, Zhang L. Xie F, et al. Among authors: yang b. Nature. 2025 Feb;638(8052):1112-1121. doi: 10.1038/s41586-024-08421-w. Epub 2025 Jan 15. Nature. 2025. PMID: 39814884
Type 2 diabetic mellitus related osteoporosis: focusing on ferroptosis.
Chen Y, Zhao W, Hu A, Lin S, Chen P, Yang B, Fan Z, Qi J, Zhang W, Gao H, Yu X, Chen H, Chen L, Wang H. Chen Y, et al. Among authors: yang b. J Transl Med. 2024 Apr 30;22(1):409. doi: 10.1186/s12967-024-05191-x. J Transl Med. 2024. PMID: 38693581 Free PMC article. Review.
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.
Wu X, Sun Y, Yang H, Wang J, Lou H, Li D, Wang K, Zhang H, Wu T, Li Y, Wang C, Li G, Wang Y, Li D, Tang Y, Pan M, Cai H, Wang W, Yang B, Qian H, Tian Q, Yao D, Cheng Y, Wei B, Li X, Wang T, Hao M, Wang X, Wang T, Ran J, Zhu H, Zhu L, Liu X, Li Y, Chen L, Li Q, Yan X, Wang F, Cai H, Zhang Y, Liang Z, Liu F, Huang Y, Xia B, Qu P, Zhu G, Chen Y, Song K, Sun M, Chen Z, Zhou Q, Hu L, Abulizi G, Guo H, Liao S, Ye Y, Yan P, Tang Q, Sun G, Liu T, Lu D, Hu M, Wang ZM, Li B, Xia M. Wu X, et al. Among authors: yang b. Lancet. 2024 Oct 26;404(10463):1668-1676. doi: 10.1016/S0140-6736(24)02135-4. Epub 2024 Oct 16. Lancet. 2024. PMID: 39426385 Clinical Trial.
Rpl12 is a conserved ribophagy receptor.
Chen Y, Hu J, Zhao P, Fang J, Kuang Y, Liu Z, Dong S, Yao W, Ding Y, Wang X, Pan Y, Wu J, Zhao J, Yang J, Xu Z, Liu X, Zhang Y, Wu C, Zhang L, Fan M, Feng S, Hong Z, Yan Z, Xia H, Tang K, Yang B, Liu W, Sun Q, Mei K, Zou W, Huang Y, Feng D, Yi C. Chen Y, et al. Among authors: yang b. Nat Cell Biol. 2025 Mar;27(3):477-492. doi: 10.1038/s41556-024-01598-2. Epub 2025 Feb 11. Nat Cell Biol. 2025. PMID: 39934334
1,815 results